Clinigen Group plc Grant of Share Options and PDMR notification (0132G)
01 November 2018 - 8:52PM
UK Regulatory
TIDMCLIN
RNS Number : 0132G
Clinigen Group plc
01 November 2018
1 November 2018
Grant of share options and PDMR notification
Clinigen Group plc (AIM: CLIN, "Clinigen" or the "Company"),
announces that, on 31 October 2018, the following Directors were
granted share options over a total of 139,251 ordinary shares
of
0.1 pence each ("Ordinary Shares"), granted under the Clinigen
Group Long Term Incentive Plan 2015. The options are nil cost
options intended to vest on 31 October 2021 subject to the
achievement of certain performance criteria.
Director/PDMR Number of Total number Total number Total number
share options of share of ordinary of ordinary
granted options now shares now shares (excluding
held held share options)
as % issued
share capital
Shaun Chilton 106,007 424,427 320,044 0.24%
--------------- ------------- ------------- -------------------
Martin Abell 33,244 217,054 19,404 0.01%
--------------- ------------- ------------- -------------------
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging managerial
responsibilities/person closely associated
a) Name Shaun Chilton
--------------------------- -------------------------------------
2 Reason for the notification
------------------------------------------------------------------
a) Position/status Chief Executive Officer
--------------------------- -------------------------------------
b) Initial notification Initial Notification
/Amendment
--------------------------- -------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
------------------------------------------------------------------
a) Name Clinigen Group plc
--------------------------- -------------------------------------
b) Legal Entity 213800OBIKGI2JYYS227
Identifier
--------------------------- -------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
------------------------------------------------------------------
a) Description Ordinary shares of 0.1 pence each
of the financial GB00B89J2419
instrument,
type of instrument
Identification
code
--------------------------- -------------------------------------
b) Nature of the Grant of Options
transaction
--------------------------- -------------------------------------
c) Currency GBP
--------------------------- -------------------------------------
d) Price(s) and Price(s) Volume(s)
volume(s)
--------------------------- ------------------ -----------------
Nil 106,007
--------------------------------------------------- -----------------
e) Aggregated 106,007
information Nil
- Aggregated
volume
- Price
- Aggregated
total
--------------------------- -------------------------------------
f) Date of the 31 October 2018
transaction
--------------------------- -------------------------------------
g) Place of the London Stock Exchange, AIM
transaction
--------------------------- -------------------------------------
1 Details of the person discharging managerial
responsibilities/person closely associated
a) Name Martin Abell
--------------------------- -------------------------------------
2 Reason for the notification
------------------------------------------------------------------
a) Position/status Chief Financial Officer
--------------------------- -------------------------------------
b) Initial notification Initial Notification
/Amendment
--------------------------- -------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
------------------------------------------------------------------
a) Name Clinigen Group plc
--------------------------- -------------------------------------
b) Legal Entity 213800OBIKGI2JYYS227
Identifier
--------------------------- -------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
------------------------------------------------------------------
a) Description Ordinary shares of 0.1 pence each
of the financial GB00B89J2419
instrument,
type of instrument
Identification
code
--------------------------- -------------------------------------
b) Nature of the Grant of Options
transaction
--------------------------- -------------------------------------
c) Currency GBP
--------------------------- -------------------------------------
d) Price(s) and Price(s) Volume(s)
volume(s)
--------------------------- ------------------ -----------------
Nil 33,244
--------------------------------------------------- -----------------
e) Aggregated 33,244
information Nil
- Aggregated
volume
- Price
- Aggregated
total
--------------------------- -------------------------------------
f) Date of the 31 October 2018
transaction
--------------------------- -------------------------------------
g) Place of the London Stock Exchange, AIM
transaction
--------------------------- -------------------------------------
-Ends-
Contact Details
Clinigen Group plc Tel: +44 (0) 1283 495
010
Shaun Chilton, Group Chief Executive
Officer
Martin Abell, Group Chief Financial
Officer
Matt Parrish, Head of Investor Relations
Numis Securities Limited Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield (Nominated
Adviser)
James Black / Tom Ballard (Corporate
Broking)
RBC Capital Markets - Joint Broker Tel: +44 (0) 20 7653 4000
Marcus Jackson / Elliot Thomas
Instinctif Partners Tel: +44 (0) 20 7457 2020
Adrian Duffield / Melanie Toyne-Sewell
/ Alex Shaw Email: clinigen@instinctif.com
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and
services company with a unique combination of businesses focused on
providing ethical access to medicines. Its mission is to deliver
the right medicine to the right patient at the right time through
three areas of global medicine supply; clinical trial, unlicensed
and licensed medicines.
For more information, please visit www.clinigengroup.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHFSUSUFFASELF
(END) Dow Jones Newswires
November 01, 2018 05:52 ET (09:52 GMT)
Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2024 to May 2024
Clinigen (LSE:CLIN)
Historical Stock Chart
From May 2023 to May 2024
